Loading...
Please wait, while we are loading the content...
Similar Documents
Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis.
| Content Provider | Europe PMC |
|---|---|
| Author | Rosa, Bruno de Jesus, Jose Paulo de Mello, Eduardo L Cesar, Daniel Correia, Mauro M |
| Copyright Year | 2015 |
| Abstract | BackgroundThe effectiveness of chemotherapy (CT) for select cases of metastatic colorectal cancer (MCRC) has been well established in the literature, however, it provides limited benefits and in many cases constitutes a treatment with high toxicity. The use of specific molecular biological treatments with monoclonal antibodies (MA) has been shown to be relevant, particularly for its potential for increasing the response rate of the host to the tumour, as these have molecular targets present in the cancerous cells and their microenvironment thereby blocking their development. The combination of MA and CT can bring a significant increase in the rate of resectability of metastases, the progression-free survival (PFS), and the global survival (GS) in MCRC patients.ObjectiveTo assess the effectiveness and safety of MA in the treatment of MCRC.MethodsA systematic review was carried out with a meta-analysis of randomised clinical trials comparing the use of cetuximab, bevacizumab, and panitumumab in the treatment of MCRC.ResultsSixteen randomised clinical trials were selected. The quality of the evidence on the question was considered moderate and data from eight randomised clinical trials were included in this meta-analysis. The GS and PFS were greater in the groups which received the MA associated with CT, however, the differences were not statistically significant between the groups (mean of 17.7 months versus 17.1 months; mean difference of 1.09 (CI: 0.10–2.07); p = 0.84; and 7.4 versus 6.9 months. mean difference of 0.76 (CI: 0.08–1.44); p = 0.14 respectively). The meta-analysis was not done for any of the secondary outcomes.ConclusionThe addition of MA to CT for patients with metastatic colorectal cancer does not prolong GS and PFS. |
| Journal | ecancermedicalscience |
| Volume Number | 9 |
| PubMed Central reference number | PMC4631576 |
| PubMed reference number | 26557880 |
| e-ISSN | 17546605 |
| DOI | 10.3332/ecancer.2015.582 |
| Language | English |
| Publisher | Cancer Intelligence |
| Publisher Date | 2015-10-15 |
| Access Restriction | Open |
| Rights License | This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. © the authors; licensee ecancermedicalscience. |
| Subject Keyword | monoclonal antibody cetuximab bevacizumab panitumumab colorectal neoplasia metastatic colorectal cancer |
| Content Type | Text |
| Resource Type | Article |
| Subject | Oncology Cancer Research |
